Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has announced a new clinical study titled ‘A ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

This therapy is one of a few drugs in mid-to-late-stage development for Parkinson’s that has displayed disease-modifying potential.

A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...

Results of a recent study strongly suggest simply getting more B vitamins in your diet could be a completely painless way of ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson's disease.

After a twitching pinky finger led to a diagnosis of young-onset Parkinson’s disease, Keith Krehbiel, then 42, stopped at a bookstore on the way home to learn more about the progressive neurological ...

Scientists have finally pinned down a protein that’s largely responsible for Parkinson’s disease. Known as PINK1, the protein has been linked to the disease for decades but its structure and how to ...

Parkinson’s disease affects over 10 million people globally, with incidence increasing after age 60. Dopamine-producing neuron loss leads to both motor and non-motor symptoms, including tremors, sleep ...

Van Andel Institute and Cure Parkinson’s have renewed a funding agreement to support the International Linked Clinical Trials Program, the world’s largest drug repurposing clinical trial initiative ...

Obstructive sleep apnea (OSA) may be associated with an increased risk of developing Parkinson disease, although early treatment with continuous positive airway pressure (CPAP) could help mitigate ...